eltrombopag   Click here for help

GtoPdb Ligand ID: 6961

Synonyms: AMG531 | Promacta® | Revolade® | SB-497115-GR
Approved drug
eltrombopag is an approved drug (FDA (2008), EMA (2010))
Compound class: Synthetic organic
Comment: Eltrombopag is a thrombopoietin receptor agonist that increases production of platelets. The structure shown here represents the compound with double bond stereochemistry as stipulated in the INN record for this drug. Representations on other chemistry databases may show alternative tautomers. The marketed drug contains eltrombopag olamine (PubChem CID 71719015, again note tautomer difference).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 114.59
Molecular weight 442.16
XLogP 6.36
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC(=O)c1cccc(c1)c1cccc(c1O)NN=C1C(=NN(C1=O)c1ccc(c(c1)C)C)C
Isomeric SMILES OC(=O)c1cccc(c1)c1cccc(c1O)N/N=C\1/C(=NN(C1=O)c1ccc(c(c1)C)C)C
InChI InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,26,30H,1-3H3,(H,32,33)/b27-22-
InChI Key XDXWLKQMMKQXPV-QYQHSDTDSA-N
No information available.
Summary of Clinical Use Click here for help
Used to stimulate platelet production in the bone marrow, in patients with chronic immune (idiopathic) thrombocytopenia (ITP, a rare blood disorder) or in patients with chronic hepatitis C who have low blood platelet counts. In August 2014, the US FDA granted approval for the additional indication, severe aplastic anemia (SAA). In June 2015, eltrombopag was granted approval from the US FDA for the treatment of children (≥ 6 yrs) with ITP.
Eltrombopag is being evaluated in clinical trials for additional indications such as myelodysplastic syndromes (Phase 3) and acute myeloid leukaemia (AML, Phase 2).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Eltrombopag activates the JAK-STAT pathway via interaction with the transmembrane domain of the thrombopoeitin receptor, leading to increased platelet production in the bone marrow (by increasing megakaryocytopoiesis).
External links Click here for help
For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)